Between 2007 and 2011, the weighting of the Pharmaceutical sector in the FTSE 100 has decreased from 8.4% to 7.1%. The closure by Pfizer of Britain’s largest foreign owned research and development facility has sparked debate of the future of Pharmaceuticals in the UK. We look at investor sentiment in UK domicile companies in comparison to foreign companies including; ;GlaxoSmithKline (LON:GSK), Astrazeneca (LON:AZN), Amylin Pharmaceuticals (NASDAQ:AMLN), Eli-Lilly and Co. (NYSE:LLY), Alkermes (NASDAQ:ALKS) and Sanofi-Aventis (EPA:SAN).